This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mayne Pharma Group Valuation

Q: What is the Fair Price of MYXDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MYXDA (A$3.54) is trading below our estimate of [[fair value]] (A$7.31)

Is MYXDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYXDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MYXDA (A$3.54) is trading below our estimate of fair value (A$7.31)

Significantly Below Fair Value: MYXDA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYXDA?

Key metric: As MYXDA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYXDA. This is calculated by dividing MYXDA's market cap by their current revenue.
What is MYXDA's PS Ratio?
PS Ratio	0.7x
Sales	AU$424.80m
Market Cap	AU$305.36m

MYXDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	156x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MYXDA's PS Ratio compare to its peers?

The above table shows the PS ratio for MYXDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	45.7x
PBP Probiotec	1.1x	6.7%	AU$242.3m
SPL Starpharma Holdings	4.7x	n/a	AU$46.0m
IHL Incannex Healthcare	64.2x	n/a	AU$65.1m
CU6 Clarity Pharmaceuticals	113x	97.0%	AU$1.3b
MYXDA Mayne Pharma Group	0.7x	9.2%	AU$305.4m

Price-To-Sales vs Peers: MYXDA is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (23.5x).

Price to Sales Ratio vs Industry

How does MYXDA's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

18 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	4.7x	48.2%
MYXDA Mayne Pharma Group	0.7x	9.2%	US$216.22m
MYX Mayne Pharma Group	1x	9.3%	US$250.72m
PBP Probiotec	1.1x	6.7%	US$160.13m

18 Companies		Estimated Growth	Market Cap
Industry Avg.	4.7x	38.4%
MYXDA Mayne Pharma Group	0.7x	73.5%	US$216.22m

No more companies

Price-To-Sales vs Industry: MYXDA is good value based on its Price-To-Sales Ratio (0.7x) compared to the Australian Pharmaceuticals industry average (7.1x)

Price to Sales Ratio vs Fair Ratio

What is MYXDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYXDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MYXDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/01/25 05:01
End of Day Share Price	2023/01/24 00:00
Earnings	2022/06/30
Annual Earnings	2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter
William Dunlop	BofA Global Research